

SPO MEDICAL RECEIVES FOUR ADDITIONAL PATENTS

Company's IP Portfolio Expanded for New Market Applications

New York, NY – Sept 14, 2009. SPO Medical Inc. ([SPOM](#)), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has been granted four additional patents by the United States Patent and Trademark Office, bringing the Company's intellectual property (IP) portfolio to a total of eight patents. These latest patents, developed by the SPO Medical engineering team, increases the Company's technological competitive edge in providing innovative, high performance oximetry solutions for a variety of market applications.

The four new patents primarily focus on several commercial applications relating to the implementation of reflectance pulse oximetry for both medical and non-medical markets. Use of pulse oximetry in these markets enables accurate and effective measurements of vital sign information in a non-invasive, convenient manner with the added ability for placement of optical sensors on various places on the body for maximum user comfort and convenience. Furthermore, SPO has addressed the challenge of vital sign measurements during motion which until now had restricted the effective use of optical sensors for professional and homecare applications. This achievement should further assist SPO in the implementation of its technology in a variety of commercial product configurations.

Michael Braunold, President and Chief Executive Officer of SPO Medical commented: "Building and maintaining a strong patent portfolio continues to be one of the strategic goals for the Company, enabling us to bring effective pulse oximetry solutions to the vital sign measurement market for both medical professional and non-medical consumer product applications. We have achieved these goals as a result of several years of research together with market experience gained from our commercial medical product line. We have several additional new patents pending which can further enhance our IP portfolio and asset value going forward."

SPO recently announced a breakthrough in the use of its core patents for measurement of the heart rate using a conventional sports wrist watch, negating the need of the traditional chest strap currently used by most sports and leisure watch manufacturers. This solution encompasses the SPO core technology in addition to resolving measurement under motion conditions. Braunold continued; "Commercially, we believe that our expanded IP portfolio asset can attract interest from both medical and non-medical corporations who are seeking commercial solutions based on our innovative technology, further contributing to potentially increasing value for the SPO Medical shareholders."

About SPO Medical:

SPO Medical ([SPOM](#)) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit www.spomedical.com and www.spobaby.com.

Forward Looking Statements:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, patent protection for our products and technologies, market acceptance of our products and new product applications, product performance, size of prospective markets, revenues assessments, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the sufficiency and availability of working capital, the introduction of competing products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008. We undertake no obligation to revise or update any forward-looking statement for any reason.

SPO Medical Contact:

Jeff Feuer, Chief Financial Officer.

Tel: 1-866-991-[SPOM](#) (7766) or email: investors@spomedical.com